Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study on the Safety, Tolerability, and Preliminary Efficacy of Single Intrathecal Injection of AAV-MECP2 in the Treatment of Rett Syndrome

NCT06856759 is registered in ClinicalTrials.gov with Guangzhou Women and Children's Medical Center as lead sponsor.

NCT NCT06856759
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06856759 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study on the Safety, Tolerability, and Preliminary Efficacy of Single Intrathecal Injection of AAV-MECP2 in the Treatment of Rett Syndrome
Lead sponsor
Guangzhou Women and Children's Medical Center
Phase
Phase 1
Overall status
Active, not recruiting
Start date
January 14, 2025
Completion date
October 23, 2029
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rett syndrome